Drug Trial Radar · NCT05099133
A Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects
Last checked: Nov 20, 2026Latest source record: Feb 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Nov 3, 2021
Primary completion
Jun 28, 2022
Study completion Jun 28, 2022
Sponsor
- Lead sponsor
- LEO PharmaIndustry
- Sponsor type
- Industry
- First posted
- Oct 29, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This trial will investigate the pharmacokinetics, immunogenicity, safety, and tolerability of LEO 138559 in healthy Japanese subjects. The trial consists of a screening period of up to 4 weeks, a single treatment with either LEO 138559 or placebo, and 8 follow-up visits to Day 85. A total of 24 healthy subjects will be enrolled in 3 dose groups (n=8 per dose group) and randomized to either LEO 138559 or placebo in a ratio of 6:2.
Conditions
- Atopic Dermatitis
Interventions
LEO 138559Drug
LEO 138559 is an antibody given by injection just under the skin.
LEO 138559 PlaceboDrug
LEO 138559 placebo is given by injection just under the skin. LEO 138559 placebo contains the same excipients in the same concentration as LEO 138559, except the medical ingredient LEO 138559.
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUC0-last: the area under the concentration-time curve from pre-dose (time 0) to the time of the last quantifiable concentrationTime frame: From Day 1 to Day 85
- AUC0-inf: area under the concentration-time curve from pre-dose (time 0) extrapolated to infinite timeTime frame: From Day 1 to Day 85
- Cmax: maximum serum LEO 138559 concentrationTime frame: From Day 1 to Day 85
- tmax: time of maximum serum LEO 138559 concentrationTime frame: From Day 1 to Day 85
- t½: terminal elimination half-lifeTime frame: From Day 1 to Day 85
- CL/F: apparent total body clearanceTime frame: From Day 1 to Day 85
- Vz/F: apparent volume of distributionTime frame: From Day 1 to Day 85
Locations
1 site in 1 country. Site status is shown where the registry gives one.
LEO Investigational Site
Los Angeles, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.